Gene Garrard Olinger
Gene Garrard Olinger serves as a Principle Science Advisor and Adjunct Faculty Member at Boston University and holds a Ph.D. degree. His research interests include the development of the countermeasures against highly lethal viral hemorrhagic fever viruses (VHFV) and alpha viruses. Previously, his team developed vaccines that have been advanced for preclinical and phase I clinical studies. He has been a PI overseeing the utility of immunotherapy against VHFV. His work has focused on the development of murine and humanized monoclonal antibody against Ebola Zaire virus under DOD and NIH funding. Continuing the effort to develop therapeutics against VHFV, his team began to screen small molecules to identify VHVF antivirals. These drug discovery efforts have led to an established effort to find therapeutic molecules for a variety of virus infections. He is an Adjunct Faculty Member of Boston University and serves as the Associate Director for High Containment Laboratory Training for Boston University’s National Emerging Infectious Diseases Laboratory (NEIDL). He has served as a subject matter expert for multiple federal and international panels related to biodefense and serves as an NIH Reviewer for HIV SBIR research.
Biography Updated on 28 December 2013